| mRNA |
MI-2 |
CTRPv2 |
pan-cancer |
AAC |
0.0046 |
0.9 |
| mRNA |
selumetinib:PLX-4032 (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0026 |
0.9 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0024 |
0.9 |
| mRNA |
BRD-K09344309 |
CTRPv2 |
pan-cancer |
AAC |
0.0061 |
0.9 |
| mRNA |
BRD-K48477130 |
CTRPv2 |
pan-cancer |
AAC |
0.004 |
0.9 |
| mRNA |
Topotecan |
CTRPv2 |
pan-cancer |
AAC |
-0.0022 |
0.9 |
| mRNA |
Sunitinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0024 |
0.9 |
| mRNA |
Nilotinib |
CTRPv2 |
pan-cancer |
AAC |
0.0024 |
0.9 |
| mRNA |
Vandetanib |
CTRPv2 |
pan-cancer |
AAC |
-0.0024 |
0.9 |
| mRNA |
BRD-K13999467 |
CTRPv2 |
pan-cancer |
AAC |
-0.0022 |
0.9 |